302. ALEMTUZUMAB FOR RELAPSING AND REFRACTORY PRIMARY SYSTEMIC VASCULITIS – A TRIAL OF EFFICACY AND SAFETY (ALEVIATE): A RANDOMISED OPEN-LABEL PHASE II CLINICAL TRIAL

Autor:	Rona M Smith, Elizabeth Broadhurst, David Jayne, Donna Goymer, Hugh Cahill, Mark McClure, Seerapani Gopaluni
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry medicine.disease Clinical trial Rheumatology Refractory Internal medicine medicine Alemtuzumab Pharmacology (medical) Open label business Systemic vasculitis medicine.drug
Zdroj:	Rheumatology. 58
ISSN:	1462-0332 1462-0324
DOI:	10.1093/rheumatology/kez063.026
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3c7f233f9bb2577cf2977e64a558470d https://doi.org/10.1093/rheumatology/kez063.026 Zobrazit plný text záznamu